\"Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to Hyaluronic acid in the treatment of neoplasia\" (Brevetto)

Type
Label
  • \"Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to Hyaluronic acid in the treatment of neoplasia\" (Brevetto) (literal)
Anno
  • 2009-01-01T00:00:00+01:00 (literal)
Alternative label
  • M. Campisi^, D. Renier^, P. Pierimarchi*, A. Serafino* (2009)
    "Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to Hyaluronic acid in the treatment of neoplasia"
    (literal)
Titolo
  • \"Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to Hyaluronic acid in the treatment of neoplasia\" (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • M. Campisi^, D. Renier^, P. Pierimarchi*, A. Serafino* (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#proprieta
  • Fidia Farmaceutici SpA (literal)
Http://www.cnr.it/ontology/cnr/brevetti.owl#tipoDiBrevetto
  • Europeo (literal)
Numero brevetto
  • PCT/IB2009/005309 (literal)
Anno di deposito
  • 2009 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • ^: Fidia Farmaceutici S.p.A. *: Istituto di Farmacologia Traslazionale del CNR (literal)
Titolo
  • \"Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to Hyaluronic acid in the treatment of neoplasia\" (literal)
Abstract
  • (EN)The present invention describes the new use in the oncologic field of bioconjugates as differentiating agents obtained by the conjugation between hyaluronic acid (HA) and a chemotherapeutic product (identified hereafter with the trade-name ONCOFID®) among which, in particular, Irinotecan, Doxorubicin, Paclitaxel, Cis-platinum and 5-Fluorouracyl (5-FU) for treating primary tumors and metastasis. In particular, the biological behaviour is described in terms of action mechanism, efficacy and tolerability of pharmaceutical preparations of derivative of ONCOFID® soluble in water. More specifically, the invention relates to the surprising biological and pharmacological effect demonstrated by formulations based on ONCOFID-S (HA-SN38 conjugates) and ONCOFID-D (HA-Doxorubicin conjugates) in promoting the differentiation of tumoral cells towards a untransformed phenotype, compared with the reference drug Irinotecan (or CPT11 whose active form is represented by SN38) and Doxorubicin. (literal)
Prodotto di
Autore CNR

Incoming links:


Autore CNR di
Prodotto
data.CNR.it